Andrew Huberman built a health empire on independent advice. He told us why he's now joining Hims' board.

Andrew Huberman has built among the internet's most mighty health audiences by translating discipline into applicable direction on sleep, fitness, hormones, supplements, and longevity.

Now, the Stanford neuroscientist and podcaster is taking a much additional straightforward function in the consumer-health economics he has helped create: Huberman is joining Hims & Hers' board.

He volition additionally formally advise the business on discipline and brand promotion and provision distinct promotion assistance through his Huberman Lab podcast.

Asked how the institution would power his coverage, Huberman told Business Insider: "We volition never display data alternatively since of a brand relationship."

The pairing brings one of health podcasting's biggest figures into the boardroom of a telehealth business expanding from tress defeat and erectile dysfunction into importance loss, testosterone, preventive care, and peptides. He'll associate another commission members, including erstwhile Netflix CFO David Wells and erstwhile DoorDash CMO Kofi Amoo-Gottfried.

It additionally ties Huberman, whose podcast and YouTube conduit attain millions of health-conscious listeners all month, to one business that can market many of the treatments he discusses.

Huberman and Hims CEO Andrew Dudum stated he volition remain liberated to shield the category broadly.

In conditions of compensation, Huberman's is much bigger than a norm commission appointment.

His annual compensation, disclosed today in an SEC filing, is value approximately $5.9 myriad before any short-form promotion work. That includes a $3.5 myriad annual prosperity fee, for two years, to advise Hims on discipline and brand marketing.

Scicomm Media, the business Huberman co-owns, volition additionally obtain $5 myriad a twelvemonth for up to three years for podcast advertising. Hims estimates Huberman's individual involvement in that agreement at approximately $2.1 myriad a year. He can additionally acquire up to another $1 myriad per twelvemonth by making short-form videos for Hims' paid promotion channels.

He volition obtain a $300,000 annualized commission bundle (including a prosperity retainer and equity award), prorated for his first term. That would location him near the top of Hims' director pay, in row alongside erstwhile FDA Deputy Commissioner Deb Autor. His multimillion-dollar advisory and media deals, however, put him in a category of his own.

The Andrews bonded complete their shared perspectives on healthcare

While Huberman has earlier served as an adviser to fitness and sleep brands, his alliance alongside Hims & Hers is distinctive — alongside fiduciary duties and firsthand involvement in the company's strategy, not fair lending specialized or promotion ability from the outside.

Huberman told Business Insider he archetypal reached out to Dudum through a mutual friend, and the two spent the final six to eight months discussing the forthcoming of person healthcare.

"We have several overlapping interests," Huberman said, including bringing the "best healthcare practices to the broadest figure of people."

"Joining the commission allows me to do that fairly than fair lone conversation concerning how Hims & Hers can do that," he added.

On a shared call Monday, the two Huberman and Dudum described their shared ambition to create personalized healthcare additional accessible. "How do you empower the masses about the globe to awareness improved and obtain additional agency in their life?" Dudum said.

Huberman stated he sees Hims as filling "this enormous gap that's existed in the middle" between the traditional healthcare system, anywhere patients can battle to get period and attention, and high-end concierge care.

"The center 95%" have to be capable to admission personalized care, he said.

Hims is not solitary in chasing that middle. A expanding collection of telehealth companies specified as Ro and Midi, longevity clinics, evaluation startups, and consumer-health brands is trying to rotate once-niche services into additional mainstream offerings.

Hims has the advantage of a ample existing client base, nearly 3 million, alongside its own drugstore and manufacturing infrastructure — and now a health podcaster alongside a huge spectators of millions who is lending his name to its expanding list of care.

Hims is betting big on optimization — a sticky area of discipline and regulation

Huberman's project is particularly notable stated Hims' shove into buzzy areas of optimization specified as testosterone and peptides, a sprawling category that has gone from a niche biohacking obsession to a additional mainstream event in latest months.

Huberman has been among the most notable mainstream voices discussing injectable peptides. Dudum, meanwhile, has been construction Hims to market them.

Hims' peptide ambitions predate the two Huberman's commission project and the latest HHS move to temporarily create several of the buzziest peptides accessible by prescription.

The business signed a agreement for a California peptide facility at the end of 2024 and announced the acquisition in February 2025. By May, Dudum was telling investors he was following peptide innovation "deeply," citing possible uses in ache management, recovery, and "generalized longevity."

In latest weeks, Hims previewed the coming initiate of Peptides+, a division on the website anywhere consumers volition be capable to admission assorted peptides (once regulatory endorsement permits) akin BPC-157, as fine as another famous health therapies akin NAD+ and vitamin B12.

Huberman stated he has no desire to advance broad use of peptides among group who don't need them. "I don't cognize if person without an hurt needs BPC and TB-500," he said.

Still, he added that one of his biggest marketing points for joining the Hims commission was their plans to authority peptide manufacturing from commencement to complete — as fine as their dedication to being at the forefront of the conversation concerning what peptides can and can't do for people. "You have to be a channel, not a dam to this benevolent of information," he said.

Dudum likewise stated the emerging earth of personalized health and longevity "needs to be navigated extremely carefully and extremely cautiously."

So, volition Huberman keep editorial independence on his podcast?

The Huberman Lab YouTube conduit has additional than 8 myriad subscribers, and his health-and-science podcast is regularly among the most famous in its category.

Huberman stated his satisfied would continue to shield benefits, risks, and doubt throughout the category. "We volition never display data alternatively since of a brand relationship," he said.

He additionally stated Hims had encouraged him to continue providing learning autonomous of "any benevolent of merchandise or platform."

He did not define how all podcast episode, social post, or abbreviated clip volition disclose his commission place and distinct promotion association alongside Hims.

The bet is that Hims can provision consumers a additional rigorous way through the flood of health information. "It really turns group into scientists of themselves," Huberman said.

The institution puts Huberman in the different stance of advising group on how to navigate the health economics during assisting market one of its biggest players.